



Bayero Journal of Pure and Applied Sciences, 17(1): 1 - 6

Received: 01/02/2024

Accepted: 15/04/2024

ISSN 2006 – 6996

PREVALENCE AND ANTIBACTERIAL RESISTANCE PROFILE OF *Escherichia coli* AND *Klebsiella* species ISOLATES OF URINARY TRACT INFECTION TO COMMON ANTIBIOTICS

Musa, F.M., *Umar, F.J., Musa, B., Aminu, A.H. and Bako, G.D.

Department of Microbiology, Kaduna State University, Kaduna, Nigeria

*Correspondence author: umar.fatima@kasu.edu.ng

ABSTRACT

Urinary tract infection (UTI) is caused mainly by both Gram positive and negative bacteria including *Escherichia coli* and *Klebsiella* species. Urinary tract infection (UTI) caused by multi-drug resistant bacteria is increasing worldwide and has become a major public health concern that requires global attention. In order to promote better treatment outcome of UTI and increase awareness of antibiotic resistance, this study was conducted among UTI patients of Barau Dikko teaching hospital Kaduna to determine the prevalence and analyze the antimicrobial resistance of *Escherichia coli* and *Klebsiella* species to common antibiotics being used for their treatment. Result from this study shows the prevalence of *Escherichia coli* to be 75% while *Klebsiella* species was 59.85%. *Escherichia coli* was resistance to the common antimicrobial drugs like Chloramphenicol 30µg (100%), Septrin (30µg)(100%), Sparfloxacin (10µg)(43%) Gentamycin 30µg (60%), Ciprofloxacin 30µg (40%), Pefloxacin (30µg)(55%), Augmentin (10µg)(100%), Amoxicillin (30µg)(100%), Streptomycin (30µg)(10%) and Tarivid (10µg)(80%). *Klebsiella* species was resistant to Chloramphenicol 30µg (60%), Septri(30µg)(100%), Sparfloxacin (10µg) (25%), Ciprofloxacin 30µg (65%), Pefloxacin (30µg)(50%), Augmentin (10µg)(100%), Amoxicillin (30µg)(30%), Streptomycin (30µg)(30%) and Tarivid (10µg)(100%). Both uropathogens analysed had P-values less than 0.05 indicating that their resistance to antibiotics is statistically significant. The occurrence of bacterial Urinary tract infection with a higher resistance rate for commonly used antimicrobials leaves the clinicians with very few options to choose drugs used for empirical treatment of UTIs. Therefore, there is the need for scientists to put more efforts in exploring alternative drugs or herbs to tackle UTI infection effectively.

Keywords: antibiotic, *Escherichia coli*, *Klebsiella* species, Prevalence, resistance, UTI

INTRODUCTION

The Urinary tract is the name given to the internal organs that collect, store and expel urine from the body, while the urinary tract infection (UTI) can be defined as condition in which bacteria are multiplying and attacking the urinary tract regardless of the position along the tract (Sule *et al.*, 2016; Klein and Hultgren, 2020). Patients suffering from asymptomatic UTI are commonly treated with antibiotics; these treatments can result in long-term alteration of the normal microbiota of the vagina and gastrointestinal tract and in the development of multidrug-resistant microorganisms (Kostakioti *et al.*, 2012; Garoy *et al.*, 2019; Agbawo *et al.*, 2020). The availability of niches that are no longer filled by the altered microbiota can increase the risk of colonization with multidrug-resistant uropathogens. Importantly, the 'golden era' of antibiotics is

waning, and the need for rationally designed and alternative treatments is therefore increasing (Christaki *et al.*, 2020 & Mukubwa *et al.*, 2023). Recent studies have used RNA sequencing to directly analyze uropathogens from the urine of women experiencing symptomatic UTIs. These studies, together with basic science and improved animal models, have been crucial in enabling us to understand the molecular details of how uropathogens adhere, colonize and adapt to the nutritionally limited bladder environment; evade immune surveillance; and persist and disseminate in the urinary tract (Kostakioti *et al.*, 2012). Although microorganisms use a diverse mechanism to get hold of drug resistance through horizontal gene transfer (plasmids, transposons and bacteriophages), recombination of foreign DNA in bacterial chromosome and mutations in diverse chromosomal locus (Bouamri *et al.*, 2015;

Sule *et al.*, 2016). The empirical usage of ciprofloxacin and cephalosporins has been threatened by the emergence of broad-spectrum beta-lactamases (Rahman *et al.*, 2019). However, antibiotic resistances are diverse to respective communities (Sabir *et al.*, 2014). *Klebsiella* spp are often resistant to many antibiotics, including cephalosporins and aminoglycosides (Nas *et al.*, 2019). β -lactam antimicrobial agents are most common treatment option for such infections.

Importantly, the 'golden era' of antibiotics is waning, and the need for rationally designed and alternative treatments is therefore increasing. Recent studies have used RNA sequencing to directly analyze uropathogens from the urine of women experiencing symptomatic UTIs (Khelfaoui *et al.*, 2020; Odongo *et al.*, 2020). These studies, together with basic science and improved animal models, have been crucial in enabling us to understand the molecular details of how uropathogens adhere, colonize and adapt to the nutritionally limited bladder environment; evade immune surveillance; and persist and disseminate in the urinary tract (Kostakioti *et al.*, 2012 & Cunha *et al.*, 2016).

The aim of this study was to determine the antibacterial resistance profile of *Escherichia coli* and *klebsiella* species isolates of urinary tract infection to common antibiotics

MATERIALS AND METHODS

The sample size for the study was determined from a standard epidemiology formula for minimum sample size calculation by (Nas *et al.*, 2019).

The sample size was calculated using the formula below;

$$n = \frac{\sum \varepsilon^2 p(1-p)}{i^2}$$

Where ε is the confidence interval, P is the prevalence rate, i is the level of precision and n is the sample size.

n=?

$\varepsilon = 1.96$

p= 9.5%

i= 5%

$$n = \frac{(1.96)^2 \times 0.095 (1-0.095)}{(5\%)}$$

$$n = \frac{3.8416 \times 0.085875}{0.0025}$$

$$n = 132.26$$

Therefore, number of samples collected was: 132.26 \approx 132.

A total of 132 samples were collected from UTI patients from Barrau Dikko Teaching Hospital,

Kaduna and was analysed for microbial susceptibility to various antibiotics.

Isolation and Identification of Bacteria

Samples of urine collected were tested within half an hour of collection. All samples were inoculated using a sterilized wire loop. Where 20 μ l of the Urine samples were cultured using streaking method on Cystine Lactose Electrolyte Deficient (CLED) agar and MacConkey agar plates after which the plates were incubated at 37 °C for 24 hours in an inverted position and colony growth was observed. *E. coli* appeared yellowish on CLED agar while *Klebsiella* species appeared mucoid pink on MacConkey agar. Gram reactions of the isolates indicated that the isolates were both Gram negative. Various Biochemical tests like indole, methyl red, Vogues Proskauer, citrate, oxidase and urease test were also done on the isolates to confirm their identity (Cheesebrough, 2006).

Standardization of Inoculum

The method of Oyeleke and Manga (2008) was used to standardize the organisms. The isolates being tested were sub-cultured on Mueller Hilton Agar (MHA) that was prepared according to the manufacturer's instruction at 37°C overnight. Colonies from the overnight growth on the MHA were inoculated into a tube containing Mueller Hinton broth until the turbidity is equivalent to the density of 0.5 McFarland standards (1.5 x10 CFU/ml).

Antibiotic susceptibility test

Antibiotic susceptibility test was performed using Kirby Bauer disk diffusion method in respect to European Committee on Antimicrobial Susceptibility Testing (EUCAST, 2014). Bio-Rad antibiotic disk that were used are; amoxicillin / clavulanic acid (AMC) (20/10 μ g), cefoxitine (FOX) (30 μ g), cefotaxime (CTX) (30 μ g), ceftazidime (CAZ) (30 μ g), imipeneme (IMP) (10 μ g), aztreoname (TMJ) (30 μ g), cefepime (FEP) (30 μ g) fosfomycine (FOS) (10 μ g), gentamicine (CN) (10 μ g), amikacine (AK) (30 μ g), tobramycine (TOB) (10 μ g), nalidixic acid (NA) (30 μ g), ciprofloxacin (CIP) (5 μ g), ofloxacin (OFX) (5 μ g) and trimethoprim sulfamethoxazole (SXT) (1.25 / 23.75 μ g).

Standardized cultures of *E. coli* and *K. pneumoniae* were spread on prepared MHA using sterile cotton swab three to four times over the entire surface of the agar, performing the streaking each time and rotating the plate about

60° to ensure even distribution of the inoculums. The plates were allowed to dry for 3-5 minutes before applying the antibiotics disks. Moreover, Forceps was used to place the proper antimicrobial-impregnated disks on the surface of the MHA agar culture plate and inverted for overnight at 37°C. The plates were then observed for susceptibility to the test antibiotics. Zones of inhibition of antibiotics against the test isolates were recorded as susceptible or resistant based on CLSI standards (Mukubwa *et al.*, 2023).

Statistical analysis

All outcome data were analysed using Statistical Package for Social Sciences (SPSS) version

18.0 software and Microsoft Excel 2010. The difference between the resistance patterns of pathogens was determined using Chi-square test of Pearson. All differences in which the probability of the null hypothesis was $p < 0.05$ were considered significant.

RESULTS

Biochemical Characteristics and Colonial Morphology of the Bacterial Isolates

The table below shows the biochemical characteristics and colonial morphology of the bacterial isolates. The isolates were confirmed to be *Escherichia coli* and *Klebsiella pneumoniae*.

Table 1: Cultural and Biochemical Characteristics of the Bacterial Isolates

Isolate	Colony morphology	Gram Reaction	CI	NI	Mot	MR	VP	IN	Lac	Probable Organism
A	Yellowish colonies on CLED	-	-	+	+	+	-	+	+	<i>Escherichia coli</i>
B	Pinkish colonies on MCA	-	+	+	-	-	+	-	+	<i>Klebsiella pneumoniae</i>

Keys:

A= *Escherichia coli*

B= *Klebsiella pneumoniae*

+: positive; -: Negative; Citr: Citrate; MRi: Methyl Red; VPi: Vogas Proskauer; Lac: Lactose; Mot.: Motility; EMB: Eusine methylene blue; MCA: MacConkey Agar.

Out of 132 urine samples examined 99(75%) were positive for *Escherichia coli* while 79(59.85%) were positive for *Klebsiella pneumoniae* as confirmed using Gram staining and biochemical tests. Results on Table 3 presents the susceptibility pattern of *E. coli* and *Klebsiella pneumoniae* isolates to antibiotics and CLSI breakpoint for each organism to the antibiotic agents were used to determine their sensitivity. Both isolates showed resistance to all the antibiotics tested against them except Gentamycin which only *Klebsiella pneumoniae* was sensitive to. Result on antibiotic resistance

percentage of *Escherichia coli* and *Klebsiella pneumoniae* shows 100% and 60% resistance to Chloramphenicol, 43% and 25% was for Sparfloxacin while 60% and 0% was for Gentamycin respectively. Also, Ciprofloxacin had 40% and 65% resistances, pefloxacin had 55% and 50% resistances, Amoxicillin had 100% and 30% resistances, Streptomycin had 10% and 30% resistances and also, Tarivid had 80% and 100% resistances by *E. coli* and *Klebsiella pneumoniae* respectively. However, both organisms were 100% resistant to Septrin and Augmentin.

Table 2: Percentage occurrence of *Escherichia coli* and *Klebsiella* species isolates from urine of UTI patients (n=132)

Isolates	Number positive	Percentage positive (%)	P value
<i>E. coli</i>	99	75.00	0.0165
<i>K. pneumonia</i>	79	59.85	

Table 3: Antibacterial sensitivity of *Escherichia coli* and *Klebsiella* species

Antibiotics	*CLSI	Mean Zone of inhibition (mm)			
		<i>Klebsiella pneumoniae</i>	Interpretation	<i>Escherichia coli</i>	Interpretation
Chloramphenicol (30µg)	≥18	11.24±0.35 ^a _b	Resistant	14.5±0.71 ^{abcd}	Resistant
Ciprofloxacin (30µg)	≥21	13.25±0.35 ^c	Resistant	15.0±0.00 ^{aefg}	Resistant
Septrin (30µg)	≥15	0.00±0.00 ^d	Resistant	0.0±0.00 ^{hi}	Resistant
Sparfloxacin (10µg)	≥30	10.75±0.35 ^a	Resistant	12.75±1.06 ^{bj}	Resistant
Amoxicillin (30µg)	≥18	8.5±0.71	Resistant	0.00±0.00 ^{hj}	Resistant
Augmentin (10µg)	≥17	0.0±0.00 ^d	Resistant	0.00±0.00 ^{ik}	Resistant
Gentamycin (30µg)	≥15	15.5±0.00 ^{ef}	Sensitive	14.75±0.35 ^{ce}	Resistant
Pefloxacin (30µg)	≥23	12.5±0.71 ^{bc}	Resistant	15.0±0.00 ^{dfl}	Resistant
Tarivid (10µg)	≥17	15.0±0.00 ^{eg}	Resistant	9.0±0.71	Resistant
Streptomycin (30µg)	≥23	15.0±0.71 ^{fg}	Resistant	16.75±0.35 ^{gl}	Resistant
P value		0.0283		0.0267	

Key: *CLSI = CLSI breakpoint for Sensitivity

Table 4: Antibiotic Resistance percentage

Organism	Chloramp henicol (30µg)	Sept rin (30 µg)	Sparflo xacin (10µg)	Genta mycin (30µg)	Ciproflo xacin (30µg)	Peflox acin (30µg)	Augum entin (10µg)	Amoxa cillin (30µg)	Strepto mycin (30µg)	Tari vid (10 µg)
<i>E. coli</i>	100	100	43	60	40	55	100	100	10	80
<i>Klebsiella pneumoniae</i>	60	100	25	0	65	50	100	30	30	100

Key: Chlo =

DISCUSSION

The most common causative agent of Urinary tract infections in the current study is *Escherichia coli* 99 (75%), followed by *Klebsiella pneumoniae* 79 (59.85%) isolates. *Escherichia coli* had the highest percentage occurrence because it has the ability to adhere, grow and resist against host defense that finally result in colonization and infection of urinary tract (Rahman *et al.*, 2019) and this conform favorably with similar studies conducted by Nordamann *et al.*, (2019) and Mukubwa *et al.*, (2023). Mukubwa *et al.*, (2023) in his study reported prevalence of 57% and 14.8% for *E.coli* and *Klebsiella species* respectively. However, in contrast to the findings

in this study, *E. coli* accounted for less than 20% of UTI cases as reported by Odongo *et al.*, (2020). In this study, *E. coli* and *Klebsiella pneumoniae* isolated from UTI showed resistance to all the common antibiotics tested against ranging from Chloramphenicol, Sparfloxacin, Ciprofloxacin, Pefloxin, Amoxicillin, Streptomycin, Tarivid, Septrin and Augmentin while only *Klebsiella pneumoniae* was sensitive to Gentamycin. This report is in correspondence with earlier studies conducted by Mukubwa *et al.*, (2023) who reported that the urinary *E. coli* and *K. pneumoniae* isolates in their study showed high resistance to most of the first and second line oral and parenteral antibiotics such as cotrimoxazole, ofloxacin, ciprofloxacin, levofloxacin, amoxicillin-

clavulanate and cefuroxime commonly used in Kinshasa, confirming the existence and challenges of antimicrobial resistance of bacterial uropathogens in Democratic Republic of Congo. The urinary *E. coli* and *K. pneumoniae* isolates in this study showed highest resistance of 100% to Septrin and Augmentin while showing remarkable resistance to all other antibiotics tested against, confirming the existence and challenges of antimicrobial resistance in bacterial uropathogens in Kaduna, Nigeria. Since *Klebsiella pneumonia* was sensitive to Gentamycin, it indicates that *Klebsiella pneumonia* can be treated using Gentamycin. This antibiotic resistance is a warning sign of emerging resistance by *E. coli* and *Klebsiella pneumoniae* infections (Gupta *et al.*, 2011 & Amawi *et al.*, 2021).

CONCLUSION

The prevalence of *Escherichia coli* in the urinary tract infection (UTI) samples tested in this study was 99 (75%) while that of *Klebsiella pneumoniae* was 79 (59.85%). Both isolates in study showed

100% resistance to Septrin and Augmentin while *Klebsiella pneumoniae* was sensitive to Gentamicin having zone of inhibition of 15.5 ± 0.00 ^{ef}. This study indicates an alarming rate of resistance of *E. coli* and *Klebsiella species* associated with urinary tract infections to common antibiotics. Therefore, immediate action is needed to prevent these resistant bacteria from spreading in both healthcare and community settings through the development of new antibiotics and vaccines. High antibiotic usage should also be reduced and proper sensitivity tests should be administered to patients before prescription of appropriate antibiotics.

Conflict of interest

There was no conflict of interest among the authors

Author's contributions

This research was a collaborative work where all the authors were involved in the sample collection process, culturing and reviewing and processing of the result.

REFERENCES

- Agbawo, O., and Ifeanchio Emeka, J. (2021). The Prevalence of UTI Pathogens in Urine Specimen Obtained from a Hospital in Rivers State Nigerian Journal of Microbiological Research (Rosemead, Calif), 5: 5: 143- 148.
- Amawi, H. A., U'wais, H. T., Nusair, M. B., et al. (2021). Management of Urinary Tract Infections and Antibiotic Susceptibility Patterns of Bacterial Isolates. Int J Clin Pract, 75 doi:10.1111/ijcp.14475.
- Cheesebrough, M. (2006). Biochemical Tests to Identify Bacteria. District Laboratory Practice in Tropical Countries, Second Edition, Pp. 62-70.
- Christaki, E., Marcou, M., and Tofarides, A. (2020). Antimicrobial Resistance in Bacteria: Mechanism Evolution and Persistence. Journal of Molecular Evolution, 88:
- Cunha, M. A., Assunção, G. L. M., Medeiros, I. M., and Freitas, M. R. Antibiotic Resistance Patterns of Urinary Tract Infections in a Northeastern Brazilian Capital. Rev Inst. Med Trop Sao Paulo. 2016; 58: 2 doi:10.1590/S1678-9946201658002.
- el Bouamri, M. C., Arsalane, L., el Kamouni, Y., and Zouhair, S. (2015). Antimicrobial Susceptibility of Urinary *Klebsiella pneumoniae* and the Emergence of Carbapenem-Resistant Strains: A Retrospective Study from a University Hospital in Morocco, North Africa. African Journal of Urology, 21: doi:10.1016/j.afju.2014.10.004.
- Folliero, V., Caputo, P., Rocca Della, M. T., et al. (2018). Prevalence and Antimicrobial Susceptibility Patterns of Bacterial Pathogens in Urinary Tract Infections in University Hospital of Campania "Luigi Vanvitelli".
- Garoy, E. Y., Gebreab, Y. B., Achila, O. O., et al. (2019). Methicillin-Resistant *Staphylococcus aureus* (MRSA): Prevalence and Antimicrobial Sensitivity Pattern among Patients - A Multicenter Study in Asmara, Eritrea. Canadian Journal of Infectious Diseases and Medical Microbiology, 2019: 8321834. doi:10.1155/2019/8321834.
- Gupta, K., Hooton, T. M., Naber, K. G., et al. (2011). International Clinical Practice Guidelines for the Treatment of Acute Uncomplicated Cystitis and Pyelonephritis in Women: A 2010 Update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis, 52: 561-564. doi:10.1093/cid/ciq257.
- Khelfaoui, M. S., Zeroug, R., Yousfi, M., and Satha, B. Prevalence and Antimicrobial

- Susceptibility Pattern of Gram-Negative Uropathogens Isolated in Public Hospital Establishment «Saad Guermech Saoudi Amar Hmaida» SkikdaAlgeria. *J Pharm Res Int.* 2020 doi:10.9734/jpri/2020/v32i3430960.
- Klein, R. D., and Hultgren, S. J. (2020). Urinary Tract Infections: Microbial Pathogenesis, Host-Patho- gen Interactions and New Treatment Strategies *Nat Rev Microbiol*, 18: 211-216
- Kostakioti, M., Hultgren, S. J. and Hadjifrangiskou, M. (2012). Molecular blueprint of uropathogenic *Escherichia coli* virulence provides clues toward the development of anti-virulence therapeutics. *Virulence*, 3, 592–594.
- Mattoo, T. K., and Asmar, B. I. (2020). Annotations on Emerging Concerns about Antibiotic-Resistant Urinary Tract Infection. *Paediatr*, 145 (2): e20193512.
- Mukubwa, G. K., Lukusa, F. N., Kavulikirwa, O. K., Liesse, J. I., Tshilolo, L. M., and Memvanga, P. B. (2023). Resistance profiles of urinary *Escherichia coli* and *Klebsiella pneumoniae* isolates to antibiotics commonly prescribed for treatment of urinary tract infections at Monkole Hospital Center, Kinshasa, Democratic Republic of the Congo, *African Journal of Clinical and Experimental Microbiology*, ; 24 (1): 51 – 60.
- Mukubwa, G.K., Lukusa, F.N., Kavulikirwa, O.K., Liesse, J.I., Tshilolo, L.M. and Memvanga, P.B. (2023). Resistance profiles of urinary *Escherichia coli* and *Klebsiella pneumoniae* isolates to antibiotics commonly prescribed for treatment of urinary tract infections at Monkole Hospital Center, Kinshasa, Democratic Republic of the Congo, *African Journal of Clinical and Experimental Microbiology*, 24 (1): 51 – 60.
- Nas, F. S., Imam, I. U., and Ali, M. (2019). Prevalence of *Klebsiella Pneumoniae* Isolated from Pregnant Women with Urinary Tracts Infections. *Archives of Urology*, 2(1): 32-38.
- Nordamann, P., Cuzon, G., and Naas, T. (2019). The real threat of *Klebsiella pneumoniae* carbapenemaseproducing bacteria. *Lancet Infectious Disease*, 9 (4):228-236.
- Odongo, I., Ssemambo, R., and Kungu, J. M. (2020). Prevalence of *Escherichia coli* and Its Antimicrobial Susceptibility Profiles among Patients with UTI at Mulago Hospital, Kampala, Uganda. *Interdisciplinary Perspective of Infectious Diseases*, 20(20).
- Odongo, I., Ssemambo, R., and Kungu, J.M. (2020). Prevalence of *Escherichia coli* and Its Antimicro- bial Susceptibility Profiles among Patients with UTI at Mulago Hospital, Kampala, Uganda. *Interdiscipl Perspect Infect Dis*, doi:10.1155/2020/8042540.
- Rahman, S., Ahmad, M., Islam, B., Ullah, A., Rahman, M., Khan, Z. H., Ahmad, S. and Ullah, I. (2019). Isolation and identification of *Escherichia coli* from urine samples and their antibiotic susceptibility pattern. *Journal of Entomology and Zoology Studies*, 7(3): 59-264.
- Sabir, S., Anjum, A. A., Ijaz, T., Ali, M. A. (2014). Isolation and antibiotic susceptibility of *E. coli* from urinary tract infections in a tertiary care hospital. *Pakistan journal of medical sciences*, 30(2):389-390.
- Shatalov, A. (2015). Prevalence and Antibiotic Resistance Pattern of *Escherichia coli* and *Klebsiella pneumoniae* in Urine Tract Infections at the La Paz Medical Center, Malabo, Equatorial Guinea. *Open Journal of Medical Microbiology*, 05: doi:10.4236/ojmm.2015.54022.
- Sule, H. and Sale, A. K. (2016). The Prevalence of *Klebsiella* Species Causing Urinary Tract Infections in Murtala Muhammad Specialist Hospital, Kano, Nigeria. *American Journal of Biomedical and Life Sciences*, 4(2): 11-15. doi:10.11648/j.ajbls.20160402.11.
- Zúniga-Moya, J. C., Bejarano-Cáceres, S. (2016). Valenzuela-Cervantes, H., et al. Antibiotic Sensitivity Profile of Bacteria in Urinary Tract Infections. *Acta Médica Costarricense*, 58 (4): 146-154.